| Single photon emission computed tomography striatal asymmetry index may predict dopaminergic responsiveness in Parkinson disease. | |
| | |
MedLine Citation:
|
PMID: 21406999 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVES: : Parkinson disease (PD) is a neurodegenerative disorder, characterized by the excellent response to l-dopa and by asymmetry of neurological signs. The aim of the present study is to investigate a possible relationship between responsiveness to l-dopa in patients with PD and asymmetry detected by single photon emission computed tomography (SPECT) with [I]FP-CIT (DaTSCAN). METHODS: : We performed a retrospective study in 20 patients with PD never previously exposed to l-dopa, who had undergone (1) a short-term l-dopa test with l-dopa/carbidopa 250/25 mg to quantify dopaminergic responsiveness, and (2) a SPECT with DaTSCAN to assess the degree of nigrostriatal neuronal degeneration. We estimated the magnitude and the duration of the response to l-dopa test as well as the striatal asymmetry index (SAI) detected by SPECT with DaTSCAN. RESULTS: : At l-dopa short-term test, most patients showed at least a mild response to the drug, and only 3 patients presented no response. Overall, the Unified Parkinson's Disease Rating Scale-Motor Examination section score at baseline was 24.9 ± 8.2, and that at peak was 21.2 ± 8 with a magnitude of the response scoring 16 ± 13.9%; the duration was 254 ± 91.2 minutes. The caudate and putamen uptakes of DaTSCAN were lower contralaterally to the most affected side. A significant positive correlation between the SAI and the magnitude of the response to l-dopa was found (r = 0.64, P = 0.002). Linear regression model provided an increase of 0.76 units of magnitude of l-dopa response every SAI unit. CONCLUSIONS: : Asymmetry resulted positively related to the magnitude of the response to l-dopa short-term test and may be usefully used to predict dopaminergic responsiveness in patients with PD. |
| | |
Authors:
|
Donatella Contrafatto; Giovanni Mostile; Alessandra Nicoletti; Loredana Raciti; Antonina Luca; Valeria Dibilio; Salvatore Lanzafame; Angela Distefano; Filippo Drago; Mario Zappia |
Related Documents
:
|
1845929 - Effects of granulocyte-macrophage colony-stimulating factor in burn patients. 9201529 - Nitric oxide synthase inhibition by l-name in leukocytopenic patients with severe septi... 19845149 - Overweight patients with severe sleep apnea experience deeper oxygen desaturation at ap... 2916389 - Right ventricular dysfunction in septic shock: assessment by measurements of right vent... 21502999 - Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome: preliminary... 15225909 - Self-inflicted burns: an eight year retrospective study in finland. 12590279 - The pattern of esophageal manometry in progressive systemic sclerosis. 12242629 - Can legislation provide a better match between demand and supply in psychotherapy? 16492269 - Right ventricular outflow tract reconstruction for tetralogy of fallot with abnormal co... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical neuropharmacology Volume: 34 ISSN: 1537-162X ISO Abbreviation: Clin Neuropharmacol Publication Date: 2011 Mar-Apr |
Date Detail:
|
Created Date: 2011-03-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7607910 Medline TA: Clin Neuropharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 71-3 Citation Subset: IM |
Affiliation:
|
*Department of Neurosciences, University of Catania; †Institute of Neurological Sciences, National Research Council, Section of Catania; and ‡Department of Experimental and Clinical Pharmacology, University of Catania, Catania, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-...
Next Document: Pregabalin in zolpidem dependence and withdrawal.